MaaT Pharma Fails to Secure European Approval for Xervyteg® in Gastrointestinal aGvHD — MaaT Pharma SA

Event summary

MaaT Pharma received a negative CHMP trend vote for MaaT013 (Xervyteg®) following a re-examination of its conditional Marketing Authorization Application (MAA) in Europe.
The CHMP maintained its view that the clinical data package, lacking a randomized control trial, does not sufficiently characterize the benefit/risk of MaaT013.
The formal CHMP opinion is expected on September 18, 2026, with MaaT Pharma evaluating all available options post-decision.
MaaT013 (Xervyteg®) is designed to treat gastrointestinal acute Graft-versus-Host Disease (GI-aGvHD), a life-threatening condition with limited treatment options.

The big picture

MaaT Pharma's failure to secure European approval for Xervyteg® highlights the regulatory hurdles faced by innovative microbiome therapies. The rejection underscores the CHMP's stringent requirements for clinical evidence, particularly in the absence of randomized control trials. This setback could delay MaaT Pharma's commercialization efforts and impact its competitive positioning in the oncology space, where microbiome modulation is increasingly seen as a key therapeutic strategy.

What we're watching

Regulatory Pathways: How MaaT Pharma will navigate the CHMP's rejection and whether it will pursue alternative regulatory strategies or additional clinical trials to secure approval.
Competitive Dynamics: Whether the absence of MaaT013 will create a larger market opportunity for existing treatments like ruxolitinib in the GI-aGvHD space.
Investor Sentiment: The impact of this setback on MaaT Pharma's stock performance and investor confidence, particularly given its reliance on microbiome-driven therapies.